| Document |
Document Title |
|
WO/2022/166799A1 |
Provided are a fused tricyclic cyclin-dependent kinase inhibitor, and a preparation method therefor and a pharmaceutical use thereof. In particular, the structure of the fused tricyclic cyclin-dependent kinase inhibitor is shown in formu...
|
|
WO/2022/166749A1 |
Disclosed are a triheterocyclic compound, a preparation method therefor, and an application thereof. Specifically, provided is a triheterocyclic compound as represented by formula IA or a pharmaceutically acceptable salt thereof. The tri...
|
|
WO/2022/169948A1 |
Described herein are novel PRMT5 inhibitors of Formula I and pharmaceutically acceptable salts thereof, as well as the pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and m...
|
|
WO/2022/166991A1 |
An indoline compound. Specifically disclosed is an application of a compound represented by formula (I) and pharmaceutically acceptable salts thereof in the preparation of drugs for treating related diseases.
|
|
WO/2022/169755A1 |
The present application discloses novel compounds of formula (I), pharmaceutical compositions containing these compounds and methods of inducing degradation of a protein, comprising contacting the protein with an effective amount of a co...
|
|
WO/2022/167627A1 |
The present invention relates to Map4K1 inhibitors of formula (I) (I), wherein A, E, G, Q, R1, R2 and R4 have the same meaning as defined in the description, to pharmaceutical compositions and combinations comprising the compounds accord...
|
|
WO/2022/166741A1 |
A macrocyclic compound containing a benzoheterocycle and acting as an EGFR kinase inhibitor. Specifically disclosed is a compound as represented by formula I or a pharmaceutically acceptable salt, a stereoisomer and a tautomer thereof, a...
|
|
WO/2022/161448A1 |
The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infecti...
|
|
WO/2022/162014A1 |
The present invention concerns aza-cryptophanes, processes for preparation thereof, and their uses, in particular as in vivo diagnostic tools when complexing a hyperpolarized noble element, or in nanoemulsions.
|
|
WO/2022/161347A1 |
A series of tricyclic compounds and the use thereof. Specifically disclosed are a compound as represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/165198A1 |
A liner in a label-liner combination is provided with a die cut portion made in the liner. The die cut portion is aligned with at least one edge in a label and a front side of the liner is attached to a backside of the label. The die cut...
|
|
WO/2022/165423A1 |
The present invention relates to pretomanid in amorphous form. The invention also relates to method of using the same, such as in a method of treating a mycobacterial infection.
|
|
WO/2022/165056A1 |
A method of treating a subject with a cancerous tumor exhibiting an inactivating mutation in the PTEN gene including administering to the subject trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrid
o [3,4-e][1,3]oxazin-2-yl)phen...
|
|
WO/2022/159491A1 |
Provided herein are compounds that are potent inhibitors of the Mycobacterium tuberculosis (MTB) RNA polymerase (RNAP), which exhibit significantly reduced activation of the human pregnane X receptor (hPXR), resulting in dramatically red...
|
|
WO/2022/159746A1 |
Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).
|
|
WO/2022/158993A1 |
The present invention relates to a method for the production of d-erythro-sphingosine and analogs thereof, wherein the method comprises a step of condensing a compound of formula (2): Formula (2), or a salt thereof, wherein R1 is hydroge...
|
|
WO/2022/155941A1 |
The invention provides a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating a disease or disorder associated with CDK2.
|
|
WO/2022/157334A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1. Furthermore, the present invention relates to agrochemical compositions which comprise compounds of formula (I), to preparation of these compositions, and t...
|
|
WO/2022/159745A1 |
Provided herein are compounds, compositions, and methods useful for modulating the activity of GCN2 and for treating related conditions, diseases, and disorders (e.g., cancer and neurodegenerative diseases).
|
|
WO/2022/153268A1 |
This invention relates to pharmaceutically acceptable tryptamine analogues and salts thereof. In particular, though not exclusively, the invention relates to formulations and uses of the same as a medicament.
|
|
WO/2022/150920A1 |
The present application relates to the treatment of plant nematode infections. For example, the application relates to the use of one or more compounds of Formula (I) as defined herein, or compositions comprising these compounds, for tre...
|
|
WO/2022/152019A1 |
A preparation method for a chiral oxazine compound, in particular relating to a preparation method for a compound of formula (I) and an intermediate thereof.
|
|
WO/2022/148422A1 |
Provided herein are Bridged Compounds having the following structures: (I) wherein R 1a, R 1b, R 1c, R 1d, R 2a, R 2b, R 2c, R 2d, R 3a, R 3b, R 3c, R 3d, R 4, R 5, R 6, R 7, R 8, m1, m2, m3, n2, n3, n4, q, X 1, X 2, Y 1, Y 2, L 1 and ri...
|
|
WO/2022/147620A1 |
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs...
|
|
WO/2022/148434A1 |
Provided are a class of pyridone multiple-membered ring derivatives and the use thereof. Specifically provided are a compound as represented by formula (VI) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/146980A1 |
Provided herein are macrocycle-based compounds or diastereomers, solvate, or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions and medicaments that include the compounds described herein as well as...
|
|
WO/2022/143424A1 |
Provided are a polycyclic pyridone derivative, a pharmaceutical composition and the use thereof. The polycyclic pyridone derivative is a compound as shown in formula (I) or a stereoisomer, a tautomer, a nitrogen oxide, a solvate, a metab...
|
|
WO/2022/143995A1 |
The present application relates to a tetracyclic compound and a medicinal use thereof, the compound having a structure as shown in formula (I). The present application also relates to a preparation method for the compound, a pharmaceutic...
|
|
WO/2022/143489A1 |
A tricyclic compound having the structure represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor and the use thereof in the prevention and treatment of a variety of diseases caused by toxi...
|
|
WO/2022/142914A1 |
The invention relates to novel crystal forms A, B and C of midostaurin, a preparation method therefor and the use thereof. The crystal forms have excellent properties in terms of physical and chemical stability and processing adaptabilit...
|
|
WO/2022/140325A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2022/138944A1 |
The present disclosure provides a pharmaceutical composition for treating and/or preventing SWI/SNF complex-dysfunction cancer. More specifically, according to the present disclosure, a compound represented by formulae (1) to (23) (the f...
|
|
WO/2022/140316A1 |
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/138987A1 |
The present invention provides a compound exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. Further provided are crystals that are...
|
|
WO/2022/138833A1 |
The present invention provides a photoelectric conversion element which is reduced in the electric field intensity dependency of a photoelectric conversion efficiency. The present invention also provides an imaging element, an optical se...
|
|
WO/2022/135610A1 |
The present invention belongs to the field of pharmaceutical chemistry, and relates to a tetracyclic compound, a pharmaceutical composition thereof and use thereof. The compound is a tetracyclic compound as shown in formula I, or a pharm...
|
|
WO/2022/134773A1 |
A macrocyclic K-RAS G12C inhibitor, a preparation method therefor and use thereof. The inhibitor can be widely used in preparation of a drug for treating cancer or tumor which is at least partially mediated by a K-RAS G12C mutation, part...
|
|
WO/2022/135432A1 |
The present invention relates to the field of medicinal chemistry and relates to a class of macrocyclic heterocyclic compounds as EGFR inhibitors, and the use thereof; specifically provided in the present invention are compounds as repre...
|
|
WO/2022/140144A1 |
Disclosed are various synthetic methods to prepare structural analogs of largazole and derivatives thereof. One structural analog is an amide isostere of largazole. Another structural analog replaces the thiazole ring of largazole with a...
|
|
WO/2022/140317A1 |
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof. Related pharmaceutical compositions and methods are also provided herein.
|
|
WO/2022/139386A1 |
The present invention relates to a heteroaryl derivative compound and a use thereof. A heteroaryl derivative of the present invention exhibits excellent inhibitory activity with respect to EGFR, and thus can be effectively used as a ther...
|
|
WO/2022/136174A1 |
The invention relates to pharmaceutical compounds of formula (I) and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of cyclin-depen...
|
|
WO/2022/136221A1 |
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therape...
|
|
WO/2022/140224A1 |
The present invention relates to compounds of e.g. formula (I) as BCL-2 inhibitors for the treatment of neoplastic, autoimmune or neurodegenerative diseases. Preferred compounds are e.g. fused 1H-pyrrolo[2,3-b]pyridine derivatives of e.g...
|
|
WO/2022/134837A1 |
Provided are a pyrrole derivative and a preparation method and use therefor. Said type of compound has obvious inhibition and blocking effects on DHODH, may be used as a DHODH specific inhibitor, may be used for preparing a drug for trea...
|
|
WO/2022/131869A1 |
The present invention provides a novel compound and an organic light-emitting device comprising same.
|
|
WO/2022/129913A1 |
The present invention relates to compounds of Formula (I), and in particular Formulae (II) and (III), which are inhibitors of c-ABL. The invention also relates to pharmaceutical compositions comprising those compounds, and to their use i...
|
|
WO/2022/129116A1 |
Indolo[3.2.1-jk]carbazole-6-carbonitrile derivatives of the formula (I) as blue fluorescent emitters in organic electroluminescent devices, more particularly OLEDs.
|
|
WO/2022/133184A1 |
The disclosure includes compounds of any one of Formulae (0)-(5), (A)-(E), (l)-(V), (11)-(20), as described herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these co...
|
|
WO/2022/130270A1 |
Compounds having the structure of Formula (I): and pharmaceutically acceptable salts thereof, wherein X1, R1, R2, R3, R4, R5 and R6 are as defined in the specification; pharmaceutical compositions comprising such compounds and salts; use...
|
